Grosse-Wilde H, Blasczyk R, Westhoff U
Department of Immunology, University Hospital of Essen, Medical School, F.R.G.
Tissue Antigens. 1992 Feb;39(2):74-7. doi: 10.1111/j.1399-0039.1992.tb01910.x.
Soluble HLA class I (sHLA-ABC) and class II (sHLA-RQP) molecules were quantitated in 16 commercially available immunoglobulin (Ig) preparations by enzyme-linked immunosorbent assays. Whereas three Ig preparations contained no detectable sHLA-ABC, all preparations showed concomitant sHLA-RQP molecules. There was a considerable variability with regard to the individual sHLA concentrations. For sHLA-RQP the values exceeded that found in human plasma of healthy individuals, suggesting that the extraction procedure may concentrate not only Ig, but also HLA class II molecules. Based on the total dosage of intravenously administered immunoglobulins (i.v.Ig), contaminating sHLA molecules may become immunogenic. Furthermore, sHLA molecules are discussed in terms of participation in the well-known immunomodulating effects of i.v.Ig therapy.
通过酶联免疫吸附测定法对16种市售免疫球蛋白(Ig)制剂中的可溶性HLA I类分子(sHLA-ABC)和II类分子(sHLA-RQP)进行了定量分析。虽然三种Ig制剂中未检测到sHLA-ABC,但所有制剂均显示存在sHLA-RQP分子。个体sHLA浓度存在相当大的差异。对于sHLA-RQP,其值超过了健康个体血浆中的值,这表明提取过程可能不仅浓缩了Ig,还浓缩了HLA II类分子。基于静脉注射免疫球蛋白(i.v.Ig)的总剂量,污染的sHLA分子可能具有免疫原性。此外,还讨论了sHLA分子参与i.v.Ig治疗中众所周知的免疫调节作用的情况。